skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.08d (Release date: 2017-08-28)
SearchBox Top
SearchBox Bottom
Lexatumumab (Code C64621)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Lexatumumab

Definition: A fully human monoclonal agonistic antibody directed against tumor necrosis factor-alpha (TNF-alpha)-related apoptosis-inducing ligand receptor-2 (TRAIL-R2) with potential antitumor activity. Mimicking the natural ligand TRAIL, lexatumumab binds to and activates TRAIL-R2, which may trigger apoptosis in and inhibit the growth of TRAIL-R2-expressing tumor cells. TRAIL-R2, also known as death receptor 5 (DR5), is a member of the TNF receptor family and is expressed on many malignant cell types.

NCI-GLOSS Definition: A substance being studied in the treatment of some types of cancer. It binds to a protein called TRAIL-R2 on the surface of some tumor cells, which may kill the tumor cells. HGS-ETR2 is a type of monoclonal antibody.

Label: Lexatumumab

NCI Thesaurus Code: C64621 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C1721684  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
anti-TRAIL R2 mAb HGS-ETR2
Anti-TRAIL Receptor 2 Monoclonal Antibody HGS-ETR2
Monoclonal Antibody HGS-ETR2

External Source Codes: 
CAS Registry Number 845816-02-6 (see NLM ChemIDplus info)
FDA UNII Code 967Q0SJD77
PDQ Closed Trial Search ID 528015
PDQ Open Trial Search ID 528015 (check for NCI PDQ open clinical trial info)
UMLS CUI C1721684

Other Properties:
     Name Value (qualifiers indented underneath)
code C64621
Contributing_Source FDA
Legacy_Concept_Name Lexatumumab
Semantic_Type Amino Acid, Peptide, or Protein
Semantic_Type Immunologic Factor
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom